In breaking news, the Supreme Court unanimously rejected a lawsuit challenging the FDA’s regulation of the abortion pill mifepristone. This decision allows the drug to remain on the market. The court ruled that the doctors and anti-abortion groups lacked standing to sue, setting an important precedent for future challenges involving mifepristone.
Mifepristone plays a significant role in medication abortion, accounting for nearly two-thirds of all US abortions. Approved by the FDA in 2000, the drug is part of a two-drug regimen used to end pregnancies and treat miscarriages. Data analysis shows that mifepristone is safer than many common prescription drugs.
Justice Brett Kavanaugh, who penned the opinion, emphasized that standing cannot be established solely based on others’ activities. President Joe Biden criticized Republicans for pushing the case, highlighting their stance on reproductive rights. Former President Donald Trump advised caution on abortion issues during a recent meeting with House GOP members.
Access to mifepristone has become crucial following the overturn of Roe v. Wade and state-level bans on abortion procedures. The court’s ruling represents a setback for the anti-abortion movement, but it also raises the possibility of future challenges to mifepristone regulations. Meanwhile, the Supreme Court is yet to announce a decision on a case involving abortion in health emergencies.
This development was reported by CNN’s Tierney Sneed and John Fritze.
